Expert Ratings For Intra-Cellular Therapies
Portfolio Pulse from Benzinga Insights
Intra-Cellular Therapies (NASDAQ:ITCI) has received mixed analyst ratings, with a recent average price target of $97.06, up from $94.00. Analysts have varied in their ratings, with some raising and others lowering their price targets. The company has shown strong revenue growth but faces challenges in profitability and asset utilization.
September 06, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Intra-Cellular Therapies has received a mix of bullish and bearish analyst ratings, with an average price target increase to $97.06. The company shows strong revenue growth but struggles with profitability and asset utilization.
The mixed analyst ratings indicate uncertainty about ITCI's short-term stock performance. The increase in average price target suggests some optimism, but challenges in profitability and asset utilization may offset this. The strong revenue growth is a positive indicator, but the overall impact is neutral due to the mixed signals from analysts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100